Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|July 1, 2020
RA Quiz: Measures of Mortality
Author(s)Ingrid Torjesen
Rheumatoid arthritis is not a life threatening condition per se, but it can have a dramatic impact on life expectancy. As a chronic systemic inflammatory condition, rheumatoid arthritis increases the risk of a number of other leading causes of death. Are you familiar with mortality risk in RA? Take this quiz.
Advertisement
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement